Cytek Biosciences (NASDAQ:CTKB) Shares Up 8.3%
Cytek Biosciences (NASDAQ:CTKB) Shares Up 8.3%
Cytek Biosciences, Inc. (NASDAQ:CTKB – Get Rating) shot up 8.3% during mid-day trading on Wednesday . The company traded as high as $13.80 and last traded at $13.80. 5,581 shares were traded during mid-day trading, a decline of 99% from the average session volume of 846,361 shares. The stock had previously closed at $12.74.
赛特克生物科技股份有限公司(纳斯达克代码：CTKB-GET Rating)周三午盘大涨8.3%。该公司股价一度高达13.80美元，最新报13.80美元。午盘成交量为5,581股，较846,361股的平均日成交量下降99%。该股此前收盘价为12.74美元。
Analyst Ratings Changes
分析师评级发生变化
A number of brokerages have issued reports on CTKB. Piper Sandler boosted their target price on Cytek Biosciences from $12.00 to $16.00 and gave the company an "overweight" rating in a research report on Wednesday, August 17th. Morgan Stanley upped their price objective on Cytek Biosciences from $11.00 to $15.00 and gave the stock an "equal weight" rating in a research report on Friday, August 12th. Finally, The Goldman Sachs Group upped their price objective on Cytek Biosciences from $15.00 to $17.00 and gave the stock a "buy" rating in a research report on Thursday, August 11th.
多家券商已经发布了关于CTKB的报告。派珀·桑德勒在8月17日(周三)的一份研究报告中将他们对Cytek Biosciences的目标价从12.00美元上调至16.00美元，并给出了该公司“增持”的评级。在8月12日星期五的一份研究报告中，摩根士丹利将赛特克生物科学公司的目标价从11.00美元上调至15.00美元，并给予该股“同等权重”的评级。最终，高盛夫妇在8月11日(星期四)的一份研究报告中将赛特克生物科学公司的目标价从15.00美元上调至17.00美元，并给予该股“买入”评级。
Cytek Biosciences Stock Up 10.1 %
Cytek Biosciences股价上涨10.1%
The firm has a fifty day moving average of $13.25 and a 200 day moving average of $11.38.
该公司的50日移动均线切入位为13.25美元，200日移动均线切入位为11.38美元。
Insider Activity at Cytek Biosciences
赛特克生物科学公司的内部活动
In other Cytek Biosciences news, CEO Wenbin Jiang sold 20,000 shares of the company's stock in a transaction on Monday, August 8th. The shares were sold at an average price of $15.09, for a total value of $301,800.00. Following the completion of the transaction, the chief executive officer now owns 7,841,541 shares in the company, valued at $118,328,853.69. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other news, CFO Patrik Jeanmonod sold 3,500 shares of the stock in a transaction dated Monday, August 1st. The shares were sold at an average price of $12.80, for a total transaction of $44,800.00. Following the completion of the sale, the chief financial officer now owns 94,994 shares in the company, valued at $1,215,923.20. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, CEO Wenbin Jiang sold 20,000 shares of the stock in a transaction dated Monday, August 8th. The stock was sold at an average price of $15.09, for a total transaction of $301,800.00. Following the sale, the chief executive officer now owns 7,841,541 shares of the company's stock, valued at approximately $118,328,853.69. The disclosure for this sale can be found here. Insiders have sold 127,000 shares of company stock valued at $1,632,675 over the last quarter. 15.90% of the stock is owned by insiders.
在Cytek Biosciences的其他消息中，首席执行官蒋文斌在8月8日星期一的一笔交易中出售了20,000股公司股票。这些股票的平均价格为15.09美元，总价值为301,800.00美元。交易完成后，首席执行官现在拥有该公司7841股，价值118,328,853.69美元。这笔交易是在提交给美国证券交易委员会的一份法律文件中披露的，该文件可通过此超链接。在其他新闻方面，首席财务官Patrik Jeanmonod在8月1日星期一的交易中出售了3500股该公司股票。这些股票以12.80美元的平均价格出售，总成交额为44,800.00美元。出售完成后，首席财务官现在拥有该公司94,994股，价值1,215,923.20美元。这笔交易是在提交给美国证券交易委员会的一份法律文件中披露的，该文件可通过这个环节。此外，首席执行官蒋文斌在8月8日星期一的交易中出售了2万股该股。该股以15.09美元的平均价格出售，总成交金额为301,800.00美元。出售后，首席执行官现在拥有7841,541股公司股票，价值约118,328,853.69美元。关于这次销售的披露可以找到这里。在上个季度，内部人士已经出售了12.7万股公司股票，价值1,632,675美元。15.90%的股份由内部人士持有。
Institutional Investors Weigh In On Cytek Biosciences
机构投资者看好赛特克生物科学公司
Several hedge funds have recently made changes to their positions in the business. Metropolitan Life Insurance Co NY boosted its stake in shares of Cytek Biosciences by 31.5% during the first quarter. Metropolitan Life Insurance Co NY now owns 6,415 shares of the company's stock worth $69,000 after buying an additional 1,536 shares during the period. Royal Bank of Canada lifted its position in Cytek Biosciences by 64.1% in the first quarter. Royal Bank of Canada now owns 5,995 shares of the company's stock valued at $65,000 after purchasing an additional 2,341 shares during the period. FMR LLC lifted its position in Cytek Biosciences by 0.5% in the second quarter. FMR LLC now owns 520,845 shares of the company's stock valued at $5,589,000 after purchasing an additional 2,616 shares during the period. American International Group Inc. lifted its position in Cytek Biosciences by 10.3% in the second quarter. American International Group Inc. now owns 53,444 shares of the company's stock valued at $573,000 after purchasing an additional 5,003 shares during the period. Finally, Ameritas Investment Partners Inc. lifted its position in Cytek Biosciences by 514.7% in the first quarter. Ameritas Investment Partners Inc. now owns 7,567 shares of the company's stock valued at $82,000 after purchasing an additional 6,336 shares during the period. Institutional investors and hedge funds own 43.54% of the company's stock.
几家对冲基金最近改变了他们在该业务中的头寸。纽约大都会人寿保险公司在第一季度将其在Cytek Biosciences的持股增加了31.5%。纽约大都会人寿保险公司在此期间又购买了1,536股，现在拥有6,415股该公司股票，价值69,000美元。加拿大皇家银行在第一季度将其在赛特克生物科学的头寸提升了64.1%。加拿大皇家银行在此期间又购买了2341股，现在持有5995股该公司股票，价值65,000美元。FMR LLC在第二季度将其在Cytek Biosciences的头寸提高了0.5%。FMR LLC现在拥有该公司520,845股股票，价值5,589,000美元，在此期间又购买了2,616股。美国国际集团(American International Group Inc.)在第二季度将其在Cytek Biosciences的头寸提高了10.3%。在此期间，美国国际集团又购买了5,003股，目前持有53,444股该公司股票，价值573,000美元。最后，ameritas Investment Partners Inc.在第一季度将其在赛特克生物科学公司的持仓提高了514.7%。Ameritas Investment Partners Inc.在此期间又购买了6,336股，目前持有该公司7,567股股票，价值82,000美元。机构投资者和对冲基金持有该公司43.54%的股票。
Cytek Biosciences Company Profile
赛特克生物科学公司简介
(Get Rating)
(获取评级)
Cytek Biosciences, Inc, a cell analysis solutions company, provides cell analysis tools that facilitates scientific advances in biomedical research and clinical applications. It offers aurora and northern lights systems, which are spectrum flow cytometers that delivers cell analysis by utilizing the fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells; and aurora cell sorter system, which leverages full spectrum profiling technology to further broaden potential applications across cell analysis.
Cytek Biosciences，Inc.是一家细胞分析解决方案公司，提供细胞分析工具，促进生物医学研究和临床应用的科学进步。它提供极光和北极光系统，这是一种光谱流动细胞仪，通过利用来自多个激光的荧光信号来区分单个细胞上的荧光标记来提供细胞分析；以及极光细胞分选系统，它利用全光谱图谱技术进一步拓宽了细胞分析的潜在应用。
Recommended Stories
推荐故事
- Get a free copy of the StockNews.com research report on Cytek Biosciences (CTKB)
- Can United Natural Foods Fight Both Inflation and the Fed?
- Mullen Automotive Is Ready To Get In Gear
- Cracker Barrel: A Tasty Treat Or Bad Apple?
- Defensive Stocks For A Volatile Market
- SunPower Is Ready To Power Up Triple-Digit Earnings Gains
- 免费获取StockNews.com关于Cytek生物科学的研究报告(CTKB)
- 联合天然食品能同时对抗通胀和美联储吗？
- 马伦汽车已做好准备投入使用
- 饼干桶：可口的款待还是坏苹果？
- 防御性股票应对动荡的市场
- SunPower准备推动三位数的收益增长
Receive News & Ratings for Cytek Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytek Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
接受Cytek生物科学日报的新闻和评级-在下面输入您的电子邮件地址，通过MarketBeat.com的免费每日电子邮件时事通讯接收对Cytek Biosciences和相关公司的最新新闻和分析师评级的每日简要摘要。